ArticleFrontiers in oncology2026
Bladder metastasis from gastric cancer presenting as acute post-renal obstruction during immunotherapy: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder metastasis from gastric cancer is extremely rare and may be misdiagnosed, particularly during immunotherapy, when new urinary symptoms can be attributed to genitourinary immune-related adverse events. We report a case of a 35-year-old man with advanced gastric cancer who initially responded to chemotherapy combined with sintilimab, an anti-Programmed Death-1 (PD-1) inhibitor. After four cycles, he developed acute kidney injury and progressive obstructive uropathy, including bilateral hydronephrosis and diffuse irregular bladder wall thickening, whereas the primary gastric lesion remained stable. Routine urinalysis revealed no such abnormalities. Cystoscopy revealed patchy follicular mucosal elevations with non-visualization of both ureteral orifices. Ureteral stent placement failed, and bilateral percutaneous nephrostomy was performed, resulting in partial recovery of the renal function. Bladder biopsy confirmed a metastatic poorly differentiated adenocarcinoma with signet-ring cell features. Immunohistochemistry was positive for caudal-type homeobox 2 (CDX2), cytokeratin 20 (CK20) and Villin, consistent with gastric origin. Despite urinary diversion, the disease progressed rapidly, leading to multiple organ failure and death in the patient. This case highlights the importance of early cystoscopy and targeted biopsy in patients receiving immunotherapy who develop new urinary symptoms or atypical urinary tract imaging findings to distinguish metastatic disease from immunotherapy-related toxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.